Investors

We’re dsm-firmenich – innovators in nutrition, health, and beauty

Share price:
Fun image of two beautiful woman on a beach in Italy. They are surrounded by sun loungers and parasols. They laugh as one of them juggles oranges. The prevailing theme is orange, as the colour pops throughout the photo. The girl in the foreground holds an orange towards the viewer as she smiles into the camera.

dsm-firmenich reports Q3 2024 trading update

dsm-firmenich announced its Q3 2024 trading update on October 31st.

Purpose-driven performance
dsm-firmenich brings together two iconic companies. We have deep roots and a bright future, with shared strengths and unrivaled expertise that drive positive impact in everything we do. Our purpose is to bring progress to life – creating a world of potential for customers, communities, consumers, and investors.

Financial calendar

February 13,  2025
Full-year 2024 results

Contact Investor relations

Whether you’re a shareholder, potential shareholder, or analyst, our Investor relations team is on hand to answer your questions.
Latest news
  • 21 November 2024

    DSM-Firmenich AG sold all of its stake in Robertet S.A.
  • 15 November 2024

    DSM-Firmenich AG sold the majority of its stake in Robertet S.A.
  • 14 November 2024

    DSM-Firmenich AG to sell part of its stake in Robertet S.A.
  • 31 October 2024

    dsm-firmenich Q3 2024 trading update
  • 24 October 2024

    dsm-firmenich receives validation from the Science Based Targets initiative for its 2045 net-zero targets
  • 2 October 2024

    dsm-firmenich completes the sale of yeast extract business to Lesaffre
  • 1 October 2024

    dsm-firmenich completes the sale of its MEG-3® fish oil business to KD Pharma Group SA
  • 8 August 2024

    dsm-firmenich concludes new €1.8 billion Revolving Credit Facility
  • 30 July 2024

    dsm-firmenich reports H1 2024 results
  • 18 July 2024

    dsm-firmenich to sell MEG-3® fish oil business to KD Pharma Group
  • 26 June 2024

    dsm-firmenich issues €800 million long-term bond
  • 14 June 2024

    DSM shareholders can voluntarily transfer their shares to dsm-firmenich before July 2, 2024, 17:45 hours CEST
  • 12 June 2024

    dsm-firmenich announces sale of yeast extract business to Lesaffre
  • 3 June 2024

    dsm-firmenich takes strategic actions to strengthen its position as a leading creation and innovation partner in Nutrition, Health and Beauty
  • 31 May 2024

    dsm-firmenich implements a cross guarantee agreement to mitigate structural subordination and establish a pari-passu debt platform
  • 29 May 2024

    Methane-reducing feed ingredient Bovaer® ready for US market launch
  • 7 May 2024

    dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2024
  • 7 May 2024

    Share repurchase program to cover share plans completed
  • 2 May 2024

    dsm-firmenich Q1 2024 trading update
  • 30 April 2024

    dsm-firmenich's progress on share repurchase program to cover share plans
  • 16 April 2024

    dsm-firmenich completes on-market repurchase of 500,000 shares to cover share plans
  • 8 April 2024

    dsm-firmenich announces repurchase of 1.5m shares to cover share plans
  • 8 March 2024

    dsm-firmenich completes the divestiture of its Jiangshan Vitamin C plant in China
  • 29 February 2024

    dsm-firmenich publishes 2023 Integrated Annual Report
  • 15 February 2024

    dsm-firmenich reports 2023 full year results
  • 14 February 2024

    dsm-firmenich to separate out Animal Nutrition & Health business from the Group
  • 12 February 2024

    dsm-firmenich completes voluntary cash offer for DSM shares
  • 8 January 2024

    dsm-firmenich makes voluntary cash offer for DSM shares
  • 31 October 2023

    dsm-firmenich reports Q3 2023 results
  • 10 October 2023

    dsm-firmenich achieves regulatory clearance in China for two HMO ingredients for early life nutrition
  • 4 October 2023

    dsm-firmenich provides additional pro forma financial information for 2022 and 2023
  • 2 August 2023

    dsm-firmenich reports H1 2023 results
  • 3 July 2023

    dsm-firmenich completes acquisition of postbiotics pioneer Adare Biome
  • 29 June 2023

    dsm-firmenich announces results of extraordinary general meeting of shareholders
  • 28 June 2023

    Trading update and acceleration of strategic actions
  • 22 May 2023

    Emmanuel Butstraen appointed as President of Perfumery & Beauty at dsm-firmenich
  • 17 May 2023

    dsm-firmenich names Katharina Stenholm as Chief Sustainability Officer
  • 9 May 2023

    dsm-firmenich launches as innovators in nutrition, health, and beauty
  • 9 May 2023

    Completion of contribution of Firmenich shares
  • 4 May 2023

    dsm-firmenich announces evolution of CEO structure per 1 September, following completion of the merger
  • 2 May 2023

    DSM provides Q1 2023 trading update
  • 1 May 2023

    Final results of the exchange offer: 96.1% of DSM ordinary shares tendered
  • 18 April 2023

    dsm-firmenich first day of trading on Euronext Amsterdam
Explore more
  • dsm-firmenich at a glance

    Who we are. Why we merged. Where we’re going.

  • Results center

    All the key financial performance information published dsm-firmenich

  • Share center

    All the key details on holding and trading shares of dsm-firmenich.